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Abstract
Human Plasmacytoid Dendritic Cells (PDCs) infiltrating solid tumor tissues and draining lymph nodes of Head and Neck
Squamous Cell Carcinoma (HNSCC) show an impaired immune response. In addition to an attenuated secretion of IFN-a
little is known about other HNSCC-induced functional alterations in PDCs. Particular objectives in this project were to gain
new insights regarding tumor-induced phenotypical and functional alterations in the PDC population. We showed by FACS
analysis and RT-PCR that HNSCC orchestrates an as yet unknown subpopulation exhibiting functional autonomy in-vitro and
in-vivo besides bearing phenotypical resemblance to PDCs and T cells. A subset, positive for the PDC markers CD123, BDCA-
2, HLA-DR and the T cell receptor ab (TCR-ab) was significantly induced subsequent to stimulation with HNSCC in-vitro
(p=0.009) and also present in metastatic lymph nodes in-vivo. This subgroup could be functionally distinguished due to an
enhanced production of IL-2 (p=0.02), IL-6 (p=0.0007) and TGF-b (not significant). Furthermore, after exposure to HNSCC
cells, mRNA levels revealed a D-J-beta rearrangement of the TCR-beta chain besides a strong enhancement of the CD3e
chain in the PDC population. Our data indicate an interface between the PDC and T cell lineage. These findings will improve
our understanding of phenotypical and functional intricacies concerning the very heterogeneous PDC population in-vivo.
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Introduction
Dendritic cells (DCs) are bone marrow derived antigen presenting
cells, such as B cells and monocytes and appear to be indispensable for
initiating appropriate immune responses. A complicated trafficking
system leads them from the bone marrow through the bloodstream to
distinct peripheral tissues, where different immature DC populations
reveal unique kinds of chemokine responsiveness [1]. Finally they
migrate to lymphoid organs in order to present processed antigens to
lymphocytes and to stimulate immune responses [2]. Two main
human DC subsets are to be distinguished: myeloid dendritic cells
(MDCs) including Langerhans cells, dermal dendritic cells and
interstitial DCs versus plasmacytoid dendritic cells (PDCs) [3].
Referring to their plasma cell-like appearance PDCs were first
identified as ‘Plasmacytoid monocytes/T cells’ in T cell areas of
lymphoid organs, later also in peripheral blood and tonsils [4].
PDCs are to a small extent capable of presenting antigens to T
cells, however their main known function is characterized by the
ability to produce large amounts of IFN-a in viral infections in-
vivo. In-vitro, IFN-a secretion is also triggered by CpG-
oligonucleotides, which consist of unmethylated CpG-dinucleo-
tides embedded in a certain sequence context within bacterial
DNA [5,6,7]. Recently, different PDC subsets with distinct
phenotype und functions have been identified [8,9].
It has been shown that human solid tumor tissues of Head and
Neck SquamousCellCarcinoma(HNSCC) areinfiltrated by PDCs,
which seem to intensely compromise proper immune functions in
this environment [10]. Cells of head and neck cancer are known to
develop molecular strategies to escape from efficient anti-tumor
immune responses. Up to now it was assumed that mainly
production of various immunosuppressive mediators by tumor cells
contributes to a heavily deranged immune defence [11].
However, the molecular mechanisms responsible for these immu-
nomodulatory transformation processes and the biosynthesis of the
immunosuppressive HNSCC microenvironment remain almost un-
known [12,13]. In this work we present a new approach to the subject
by introducing a novel, functionally distinct subpopulation bearing
phenotypical resemblance to PDCs and T cells in HNSCC.
Results
Phenotypical alterations in the PDC population
subsequent to incubation with HNSCC cell-lines in-vitro
were narrowed to incomplete maturation and up-
regulation of the receptors CD4 and CD45RA
Classical PDC maturation is phenotypically defined by the up-
regulation of CD123, CD80, CD83, CD86 and HLA-DR in addition
to the down-regulation of the C-type Lectin BDCA-2 [14,15,16].
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lines for 12 hours, PDCs show only a partial maturation. Unlike
classical maturation, HNSCC has neither any impact on HLA-DR
nor on the co-receptors CD80, CD83 and CD86. BDCA-2 was
significantly down-regulated (p=0.01), while CD123 was up-
regulated (p=0.07). In some donors HLA-DR was strongly down-
regulated. Furthermore, a highly significant surface elevation of CD4
(p=0.009) and CD45RA (p=0.001) was observed (Figure 1A).
All other analysed receptors, which were lineage markers (CD3,
CD14, CD16, CD19, CD20, CD56), Fc-receptors (CD16, CD23,
CD32, CD64), further T cell markers (CD1a, CD2, CD3, CD5,
CD8, CD25, GITR, CTLA-4), activation markers (CD40, CD69),
stem cell markers (CD34, CD117, CD133) and the myeloid
marker CD11c, were not significantly affected by tumor cell-lines
in the classical PDC population (data not shown).
HNSCC induced a TCR-ab positive CD123+ BDCA2+
HLADR+ subset
HNSCC induced a TCR-ab positive CD123+ BDCA2+
HLADR+ subset. This subset was significantly (p=0.009) up-
regulated subsequent to stimulation with HNSCC cell-lines for
12 hours and enhanced from 1.6% (mean) +/21.5% (SD) in the
medium control to 4.5% (mean) +/20.88% (SD) after stimulation
(Figure 1B). Furthermore it was located in the centre of the PDC
population when back-gated to the FACS forwards/sidewards
scatter (Figure 2) and exhibited a double-positive phenotype for
CD4 and CD8 in-vitro, however, partly a double-negative pheno-
type in-vivo (data not shown). Furthermore, this subset was positive
for CD2, CD3, CD5andCD7(Figure 3).CD1a,CTLA-4,FOXP3,
CD34 and CD117 were not expressed. Some donors revealed
CD25dim+/TCR-ab+ cells, however we could not show any
significance for the expression of the surface marker CD25. CD25
positive cells were likewise located in the PDC region (SSC/FSC)
and represented larger cells than the remaining TCR-ab positive
subset (Text S1). Doublets were excluded by gating FSC-H against
FSC-A. The TCR-c/d could not be detected.
Furthermore a RT-PCR was performed subsequent to stimu-
lating and cell-sorting the PDC population. Compared to the
medium control, a distinct up-regulation of CD3e and the pre-
TCRa mRNA was detected after incubation with HNSCC. CD3c
and CD3d mRNA could not be detected. As T cells do express
CD3c and CD3d mRNA, these lanes were used as a control in
order to exclude a contamination by ordinary T cells.
Furthermore the data comprise a strong indication for the up-
regulation of the recombined D-J-b chain in the PDC population
subsequent to stimulation with HNSCC cell-lines (Figure 4).
The TCR-ab positive CD123+ HLA-DR+ BDCA-2+ cells
revealed distinct functional properties in-vitro and
in-vivo
We analysed the cytokine production (IL-2, IL-4, IL-6, IL-8,
IL-10 and TGF-b)o ft h eT C R - ab positive subset in-vitro and in single
cell suspensions of metastatic lymph nodes from HNSCC patients. The
results were compared to the cytokine production of the TCR-ab
negative PDC population. We were able to significantly demonstrate a
higher intracellular production of IL-2 and IL-6 in the TCR-ab
positive PDC population in-vitro and in-vivo (p=0.02). A dominant
IL-6 secretion was highly significant (p=0.0007) for the TCR-ab
positive cells in-vivo (Figure 5 and 6). 90–100% of the TCR-ab+ cells
were positive forIL-2 and 100% of the TCR-ab+cells were positive for
IL-6 in each sample (p,0.001). The classical PDCs do not confidently
produce IL-2. The FACS plots show a shift in the population, however
no circumscribable positive subset. About 80% of the classical PDCs
were positive for IL-6 (p,0.001).
Figure 1. Incomplete maturation in the PDC population and induction of the TCR-ab positive subset post stimulation. A CD123+ HLA-
DR+ BDCA-2+ cells showed an incomplete maturation subsequent to stimulation with HNSCC. BDCA-2 was down-regulated (p=0.011) while CD123
was up-regulated (p=0.07). Furthermore, a highly significant up-regulation of CD4 (p=0.009) and CD45RA (p=0.001) was observed. B TCR-ab
positive, CD123+ HLA-DR+ BDCA-2+ cells were significantly (p=0.009) induced subsequent to stimulation with HNSCC cell-lines for 12 hours. The
Mean Fluorescence Intensity (MFI) was determined separately for each Isotype control and each subpopulation and then subtracted from the positive
results before calculating the relative MFI. Figure 1 shows the relative MFI after incubation with HNSCC in relation to the medium control MFI. The
control MFI is equal to 1 in each case by definition. The data are presented in box plots, showing the median, the lower and the upper quartile.
doi:10.1371/journal.pone.0015997.g001
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Expansion of the TCR-ab+ subset could not be assured, as the
TCR-ab was barely detectable after cross-linking CD3/28. Never-
theless, we incubated isolated CD123+ BDCA-2+ HLA-DR+ cells
with HNSCC and the T cell Expansion Kit (Miltenyi) in addition to
IL-2 (20–200 U/l) for 3–7 days. Less TCR-ab+ cells were revealed
(after 1–7 days) when compared to the control with HNSCC after
24 h (Figure 7). Presumably this can be attributed to the down-
regulation of the TCR subsequent to cell activation. However, the
CD123+ BDCA-2+ HLA-DR+ cells, which usually do not survive
longer than 12–24 hours in-vitro, survived up to 7 days subsequent to
stimulation with the Expansion Kit and IL-2. Incubation with IL-4
Figure 2. FACS plots showing the TCR-ab positive subset subsequent to stimulation with HNSCC. An IgM-Isotype control was used as a
negative control. Cell viability was confirmed by staining with Annexin and PI. TCR-ab positive cells were significantly (p=0.009) enhanced from 1.6%
(mean) +/21.5% (SD) in the medium control to 4.5% (mean) +/20.88% (SD) in healthy donors after stimulation with tumor in-vitro. The TCR positive
subset expressed the surface markers CD123, HLA-DR (not shown) and BDCA2 and was located in the centre of the PDC population when back gated
to FSC/SSC. The black dots represent the TCR-ab positive cells in the lower scattergrams.
doi:10.1371/journal.pone.0015997.g002
A New Subset in Tumor Immunity
PLoS ONE | www.plosone.org 3 January 2011 | Volume 6 | Issue 1 | e15997(1–10 pg/ml), IL-6 (500–4000 pg/ml), IL-8 (500–1000 pg/ml), IL-
10 (10 ng/ml) and TGF-b (10 ng/ml) did not lead to any significant
expansion of the subset. Cytokine concentrations were chosen
according to the cytokine secretion of the HNSCC cell lines, which
induced the TCR-ab+ subset [17].
The transcription factor Notch-1 is up-regulated in the
PDC population subsequent to incubation with HNSCC
cell-lines
As the transcription factors Notch-1, GATA-3 and SPI-B have
been shown to control the T cell/PDC lineage decision in early
thymocytes [18], the mRNA levels were analysed in the PDC
population after stimulation with HNSCC. Indeed, we found
elevated levels of Notch-1 mRNA, however no up-regulation of
GATA-3 and SPI-B mRNA could be detected (Figure 4).
Discussion
Numerous pro-inflammatory, pro-angiogenetic and immuno-
suppressive cytokines [11,17,19,20] within the HNSCC microen-
vironment and in the serum of tumor patients are suspected of
benefiting tumor growth and metastasis besides severely impairing
the function of various immune cells [21,22,23]. Especially IL-6,
Figure 3. Surface marker expression on the TCR-ab+ cells. The TCR-ab positive subset expressed the surface markers CD2, CD3, CD4, CD5, CD7 and CD8.
doi:10.1371/journal.pone.0015997.g003
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proven to be an independent predictor of poor survival [25]. Solid
HNSCC and metastatic lymph nodes have been found to be
infiltrated by various species of immune cells including PDCs,
which are supposed to participate in the formation of the HNSCC
microenvironment due to functional alterations [10,26,27].
PDCs in HNSCC
In accordance with the postulation above, we observed
functionally disabled PDCs after stimulation with tumor. As
already revealed in non-small cell lung cancer [28] we concor-
dantly demonstrated an impaired phenotypical maturation in the
PDC population in-vivo and after stimulation with HNSCC cell-
lines for 12 hours in-vitro.
Consistent with normal maturation CCR7 [29] and CD123 are
up-regulated whilst BDCA2 is down-regulated. In contrast the co-
stimulatory receptors (CD80, CD86) and CD83 are not influenced
by the tumor, HLA-DR expression is even decreased in many
cases and the early activation marker CD25 [30] is only presented
by a small subpopulation [unpublished data]. As we have already
shown in earlier studies, the immature phenotype also correlates
with a disturbed functional maturation. PDCs stimulated with
CpG-2216 reveal an impaired IFN-a production in the HNSCC
environment [29].
TCR-ab positive CD123+ HLA-DR+ BDCA-2+ cells in
HNSCC
First of all the discovery of the TCR-ab on a subpopulation of
CD123+ HLA-DR+ BDCA-2+ cells confronted us with two main
questions: did we really find a new population expressing the TCR
and not activated, blastic T cells similar to the recently
characterised CD4+ Th-APC [31]? Furthermore, as Busch et al.
[32] discovered the transfer of T cell surface molecules to DCs
upon CD4+ T cell priming: did we observe a TCR exchange or
production?
Therefore we performed a RT-PCR for the earliest point of
recombination: the DJ-b chain, for the CD3 chains and the pre-
TCRa. After stimulation with HNSCC cell-lines, a weak induction
of the DJ-b chain was exhibited whilst no trace was visible in the
medium control. The other striking point is the difference in the
Figure 4. Impact of HNSCC on mRNA-levels in the PDC population. We demonstrated an increase of the pre-TCRa-receptor mRNA-levels
besides a strong enhancement of the CD3e chain mRNA-levels after stimulation with HNSCC in the PDC population. Both, the CD3d and c chain were
not detectable. In order to prove recombination of the TCR-b chain in the PDC population, we also analysed mRNA up-regulation for D-J-b, the
earliest point of recombination of the TCR-b chain. Indeed, after stimulation with tumor we did detect D-J-b mRNA. For a positive control PDC
depleted PBMCs were used in order to demonstrate the presence of CD3d and c mRNA in contrast to the isolated CD123+ HLA-DR+ BDCA-2+
population. The pre-TCRa mRNA could hardly be detected.
doi:10.1371/journal.pone.0015997.g004
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population compared to the PBMC control. Whilst the lympho-
cytes in the PBMC control express the CD3d, e and c chain
mRNA, the PDC population only exhibits a weak expression of
the CD3e chain which is clearly enhanced after stimulation.
Similar results are demonstrated for the pre-TCRa mRNA. These
findings indicate an intracellular production of parts of the T cell
receptor and exclude a contamination by ordinary T cells.
Cytokine expression
Due to the size of the TCR positive subpopulation, the FACS
facility was not able to reach a high purity by cell sorting this
subset, so we had to reduce functional analyses to the FACS.
Currently we are working on expanding cocktails for this
subpopulation.
By FACS analysis we were able to demonstrate significantly
higher amounts of intracellular IL-2 and IL-6 for the TCR positive
subpopulation. Especially production of IL-6 was highly significant
in-vivo. Furthermore, the production of TGF-b was observed in
the TCR positive subset. Therefore, we postulate a role for this
population in tumor growth, metastasis and induction of tolerance.
IL-6 and likewise CD25/HLA-DR+ T cells, which are at least
phenotypically associated with the new subpopulation, have been
proven to be a predictor of poor survival in HNSCC [25,33].
Additionally, IL-6 promotes growth, survival, invasiveness and also
secretion of IL-6 in different tumors in-vivo [34,35,36]. Further-
more, also the secretion of TGF-b has been linked to epithelial-
mesenchymal transition, metastasis and the induction of oncogenic
properties [37,38,39] besides impairing the secretion of IFN-a in
PDCs [40]. Doubtless, these postulations are speculative at the
time. However, as Baban et al. and Matsui et al. [8,9] have already
demonstrated functionally distinct PDC subsets, we consider it
possible that this minor subset has a relevant impact on HNSCC.
Origin of the subpopulation
A further question concerns the cell lineage of this subpopula-
tion. The TCR positive CD123+ HLA-DR+ BDCA-2+ cells may
originate from a T cell subpopulation exhibiting PDC features
besides lacking the CD3 d and c chain. Likewise they may
originate from a subpopulation of PDCs. Similar to other recently
discovered populations showing an interface between two lineages
[41,42], a determination of the lineage will become a major
challenge, as a mutual contamination cannot be absolutely
excluded during isolation. A possible approach could include the
detection of IFN-a and the transcription factor E2-2 [43].
As NOTCH-1 has been shown to regulate PDC versus T cell
lineage decision through control of GATA-3 and SPI-B [18] we
analysed the mRNA levels of the PDC population subsequent to
stimulation. However, although NOTCH-1 mRNA was up-
regulated after exposure to HNSCC cell-lines, we could not
demonstrate any expression of GATA-3. On the contrary, the
levels of SPI-B, which is supposed to inhibit T-, NK- and B cell
development [44], were actually slightly elevated. In this respect
we were able to exclude the relevance of this pathway for the TCR
positive subpopulation.
Besides expanding the new subset for functional analysis versus
demonstrating their relevance as non-proliferating bystander T
cells [45], determination of the lineage and functional analysis of
the TCR signalling, in-vivo models will have to clarify the
relevance of this population in HNSCC.
Materials and Methods
Ethic statements
An ethic proposal concerning the abstraction of tumor tissue
during operations of tumor patients was approved by the ethics
committee, Campus Lu ¨beck. All experiments have been conduct-
ed according to the principles expressed in the Declaration of
Helsinki. Written informed consent was obtained in each case
before abstracting tissue and blood (Text S2, S3, S4).
Isolation of PDCs
For in-vitro studies PDCs were isolated from human peripheral
blood provided by the blood bank of the University Hospital
Lu ¨beck, Germany. Blood donors were 18–65 year-old healthy
donors who were tested to be negative for allergies. Additional
exclusion-criteria were manifest infections during the last 4 weeks,
fever or medication of any kind. Peripheral mononuclear blood
cells (PBMCs) were obtained from buffy coats by Ficoll-
Hypaque density gradient centrifugation as described elsewhere
[46]. PDCs were isolated by magnetic bead separation using
magnetic labelled anti-BDCA-4 antibodies (Miltenyi, Bergisch
Gladbach, Germany).
Single-cell-suspensions
After removal of fat, blood or necrotic areas, tumor draining
lymph nodes were washed in phosphate buffered saline (PBS), cut
into little pieces in a Petri dish covered with PBS and washed again
with PBS by gravity sedimentation in a 50 ml conical centrifuge
tube. The tissue pieces were then covered with 31,5 mg
Collagenase/ml PBS and 3,99 mg/ml Hyaloronidase/ml PBS in
DMEM and incubated in a 37uC water bath for 30–120 minutes.
Digestion was checked every 30 minutes. In a further step 33,4 mg
Dispase/ml PBS was added for 30–60 minutes. Brefeldin A
Figure 5. Cytokine production in the TCR-ab positive subset.
The TCR-ab positive cells produced higher levels of IL-2 and IL-6 when
compared to the TCR-ab negative CD123+ HLA-DR+ BDCA-2+ cells. All
results were significant (p=0.02), a dominant IL-6 secretion (p=0.0007)
was highly significant for the TCR-ab positive cells in-vivo. The Mean
Fluorescence Intensity (MFI) was determined separately for each Isotype
control and each subpopulation and then subtracted from the positive
results before calculating the relative MFI. Figure 5 shows the relative
MFI of the TCR-ab positive subset in relation to the MFI of the classical
PDC population. The MFI of the classical PDC population is equal to 1 in
each case by definition. The data are presented in box plots, showing
the median, the lower and the upper quartile.
doi:10.1371/journal.pone.0015997.g005
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digest was then passed through a 100 mm nylon mesh in order to
remove clumps and washed several times.
Cell cultures
The permanent HNSCC cell lines BHY (DSMZ Germany),
PCI-1 and PCI-13 (generously provided by Prof. T. Whiteside,
Pittsburgh Cancer Institute) were cultured in Dulbecco’s Modified
Eagle Medium (DMEM, Gibco, New York, USA) supplemented
with 10% FCS, 1 mM glutamine, and 0.1 mM sodium pyruvate.
All compounds were purchased Endotoxin tested.
Incubation
Depending on the amount of cells, PDCs were incubated with
HNSCC supernatants or co-cultured with the tumor cell-lines
BHY, PCI-1 and PCI-13 at a concentration of 480000cells/60 ml
in U-shaped 96 well plates or flat bottomed 12 well plates for 12
hours. For cell expansion, the T cell Expansion Kit (Miltenyi) was
Figure 6. FACS plots showing the cytokine production in the TCR-ab positive and negative subset. FACS plots showing IL-2 and IL-6
production in-vivo. The black circles identify the TCR-ab positive population. In this sample, the TCR-ab positive cells comprised 2% of the PDC
population and partly produced TGF-b. TGF-b secretion was analysed four times.
doi:10.1371/journal.pone.0015997.g006
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IL-2 (20–200 U/l, BD), IL-4 (1–10 pg/ml, BD), IL-6 (500–
4000 pg/ml, BD), IL-8 (500–1000 pg/ml, BD), IL-10 (10 ng/ml,
BD) and TGF-b (10 ng/ml, BD) were added for 1–7 days.
Flow cytometry
PDCs were identified as CD123-PE positive, HLA-DR-PerCP
positive, lineage cocktail-FITC (CD3, CD14, CD16, CD19,
CD20, CD56; Becton Dickinson Heidelberg, Germany) negative
and BDCA2-APC/PE (Miltenyi Biotec, Bergisch-Gladbach,
Germany) positive cells. Surface antigen staining was performed
using the antibodies CD1a-FITC, CD2-PE, CD3-PE, CD4-
PERCP, CD4-APC-CY7, CD8-ARC-CY7, CD11c-APC, CD14-
APC, CD16-FITC, CD19-FITC, CD20-APC, CD23-PE, CD-25-
APC/APC-CY7, CD32-FITC, CD34-PERCP, CD38-APC/PE-
CY7, CD40-APC, CD44-PE, CD56-PE, CD64-FITC, CD69-
FITC, CD80-FITC, CD83-FITC, CD86-PE, CTLA4-PE, CCR7-
PE-CY7, CD117-APC, TCR-a/b-PE/FITC, TCR-c/d -APC,
IFNg-FITC, IL-4 PE, IL-10 APC (Becton Dickinson Heidelberg,
Germany), CD123-APC/FITC, BDCA4-APC, CD45RA-FITC,
CD133-PE (Miltenyi Biotec, Bergisch-Gladbach, Germany),
CD25-FITC/PE-CY7, CD127-FITC, (eBioscience, San Diego,
USA) and GITR-FITC, IL-2 FITC, IL-6-FITC, IL-8-FITC,
TGF-b-PE, TNF-a-FITC (R&D Systems, Minneapolis, USA).
The Isotype PE IgG1/IgG2a, the Isotype APC IgG1/IgG2a and
the Isotype Fitc IgG1/IgG2b (Becton Dickinson, Heidelberg,
Germany) were used as negative controls. The Mean Fluorescence
Intensity (MFI) was determined separately for each Isotype control
and each subpopulation and then subtracted from the positive
results before calculating the relative MFI. The figures 1 and 4
show the relative MFI after incubation with HNSCC in relation to
the medium control MFI and to the MFI of the classical PDC
population (negative for the TCR-ab), respectively. The control
MFI is equal to 1 in each case by definition. Early apoptotic or
dead cells were detected by staining the cells with Annexin-V-
FITC and Propidium-Iodide-PE (Becton Dickinson, Heidelberg,
Germany). Doublets were excluded by gating FSC-A against FSC-
H. Only singlets were analysed. CD107a was up-regulated in the
PDC population subsequent to stimulation with HNSCC,
indicating cytokine secretion.
The amount of 2?10
5 PDCs was incubated on ice in 50 ml1 %
BSA (in PBS) with 1-2 ml of each antibody for 15 minutes. Then
the cells were washed three times in 500 ml 1% BSA and
subsequently analysed on a FACSCanto (Becton Dickinson)
equipped with FACS DIVA software. Intracellular staining was
performed with the eBioscience-staining-buffer-set according to
the eBioscience protocol. Cell sorting was performed with a Dako
moFlow.
RT-PCR
After cell-sorting and verification of cell purity and viability,
mRNA was isolated with the RNeasy kit (Qiagen, Hilden,
Germany). For RT-PCR we used the Qiagen One-step RT-
PCR kit according to protocol and publications. The primers are
listed in table 1. In order to minimize the risk of falsified results by
proliferating cells, RT-PCR was performed directly after sorting
the PDC population. Stimulated PDCs we isolated at a purity
.99%, PDCs in the medium control at a purity .92%.
Subsequent to electrophoresis, the PCR products were
sequenced at the University of Kiel.
Statistical analysis and samples
The Kolmogorow-Smirnow test did not show a normal
distribution. Therefore we performed the Wilcoxon-Mann-With-
ney test for statistical analysis. p,0.05 was considered to be
marginally significant. 5–12 samples were analysed per surface
marker, cytokine and tissue. Only those FACS plots showing a
clear separation between the subpopulations were included.
Doublets were excluded by gating FSC-A against FSC-H. Cells
were extracted from the blood of healthy donors and metastatic
Figure 7. We incubated isolated CD123+ BDCA-2+ HLA-DR+ cells with HNSCC and the T cell Expansion Kit (Miltenyi) in addition to
IL-2 (20-200 U/l) for 3-7 days. Less TCR-ab+ cells were revealed (after 1-7 days) when compared to the control with HNSCC after 24 h. Presumably
this can be attributed to the down-regulation of the TCR subsequent to cell activation.
doi:10.1371/journal.pone.0015997.g007
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for cytokine analysis. Tissue histology was determined by the
Institution for Pathology, University of Lu ¨beck.
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